Figure 6.
Syndecan-2 regulates HSC quiescence through Cdkn1c. Representative cell cycle analysis of shSdc2 Clone #1–treated (A) and shSdc2 Clone #2–treated (B) and shCtrl-treated Sdc2+34–KSL cells. (C) Percentages of 34–KSL cells in G0, G1, and G2/S/M phases in each group (n = 4-5 replicates per group). (D) Quantitative reverse transcription polymerase chain reaction analysis for the expression of Cdkn1c in Sdc2+ and Sdc2– BM 34–KSL cells treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 and shCdkn1c (n = 3-12 replicates per group). (E) Quantitative reverse transcription polymerase chain reaction analysis for the expression of Cdkn1a, Cdkn1b, and p16 in Sdc2+ and Sdc2– BM 34–KSL cells treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 and shCdkn1c (n = 3-12 replicates per group). (F) Numbers of CFU-GEMMs from 250 Sdc2+ HSCs treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 + shCdkn1c. (G) Percentages of Sdc2+ HSCs in G0 after treatment with shSdc2 or shCtrl and 5 µM SIS3 or vehicle for 24 hours (n = 3-6 replicates per group). (H) Percentages of CD150+CD48–34–KSL LT-HSCs in G0, G1, and G2/S/M phases from Ki-67/7-AAD analysis (n = 3-4 replicates per group). (I) At left, representative flow cytometric analysis showing phospho-SMAD3 expression in 34–KSL, 34–KSL Sdc2–, and 34–KSL Sdc2+ HSCs as baseline and after TGFβ stimulation for 30 minutes; at right, quantification of the percent phospho-SMAD3 cells within each population. (J) Quantification of CFU-GEMMs from 100 Sdc2+ HSCs or Sdc2– HSCs treated with 5 µM SIS3 or vehicle (n = 5 mice, pooled for sort; n = 4 replicates per group). (K) Percent 34–KSL cells (percentage of live cells) after SIS3 treatment of Sdc2+ and Sdc2– HSCs for 7 days in TSF media (n = 3-6 replicates per group). (L) Volcano plots depicting differentially expressed genes in Sdc2+ HSCs vs Sdc2– HSCs. Differentially expressed genes were detected with parameters of P < .05, and fold change (FC) >2 or less than −2. (M) Heat map depicting Ingenuity Pathway Analysis comparing Sdc2+ HSCs and Sdc2– HSCs (n = 10 mice pooled to sort each population; n = 3 replicates per population; comparisons made between individual samples). (N) Heat map depicting selected differentially expressed genes within Hematological System Development, and (O) Cell Growth and Proliferation genes from Ingenuity Pathway Analysis of 34–KSL HSCs, Sdc2– HSCs, and Sdc2+ HSCs (n = 10 mice pooled to sort each population; n = 3 replicates per population). Error bars = standard error of the mean; statistics denote 2-way analysis of variance followed by unpaired Student t test. *P < .05, **P < .01, ***P < .001, ****P < .0001. FDR, false discovery rate; ns, not significant; SSC-A, side scatter area.

Syndecan-2 regulates HSC quiescence through Cdkn1c. Representative cell cycle analysis of shSdc2 Clone #1–treated (A) and shSdc2 Clone #2–treated (B) and shCtrl-treated Sdc2+34KSL cells. (C) Percentages of 34KSL cells in G0, G1, and G2/S/M phases in each group (n = 4-5 replicates per group). (D) Quantitative reverse transcription polymerase chain reaction analysis for the expression of Cdkn1c in Sdc2+ and Sdc2 BM 34KSL cells treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 and shCdkn1c (n = 3-12 replicates per group). (E) Quantitative reverse transcription polymerase chain reaction analysis for the expression of Cdkn1a, Cdkn1b, and p16 in Sdc2+ and Sdc2 BM 34KSL cells treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 and shCdkn1c (n = 3-12 replicates per group). (F) Numbers of CFU-GEMMs from 250 Sdc2+ HSCs treated with shCtrl, shSdc2, shCdkn1c, or shSdc2 + shCdkn1c. (G) Percentages of Sdc2+ HSCs in G0 after treatment with shSdc2 or shCtrl and 5 µM SIS3 or vehicle for 24 hours (n = 3-6 replicates per group). (H) Percentages of CD150+CD4834KSL LT-HSCs in G0, G1, and G2/S/M phases from Ki-67/7-AAD analysis (n = 3-4 replicates per group). (I) At left, representative flow cytometric analysis showing phospho-SMAD3 expression in 34KSL, 34KSL Sdc2, and 34KSL Sdc2+ HSCs as baseline and after TGFβ stimulation for 30 minutes; at right, quantification of the percent phospho-SMAD3 cells within each population. (J) Quantification of CFU-GEMMs from 100 Sdc2+ HSCs or Sdc2 HSCs treated with 5 µM SIS3 or vehicle (n = 5 mice, pooled for sort; n = 4 replicates per group). (K) Percent 34KSL cells (percentage of live cells) after SIS3 treatment of Sdc2+ and Sdc2 HSCs for 7 days in TSF media (n = 3-6 replicates per group). (L) Volcano plots depicting differentially expressed genes in Sdc2+ HSCs vs Sdc2 HSCs. Differentially expressed genes were detected with parameters of P < .05, and fold change (FC) >2 or less than −2. (M) Heat map depicting Ingenuity Pathway Analysis comparing Sdc2+ HSCs and Sdc2 HSCs (n = 10 mice pooled to sort each population; n = 3 replicates per population; comparisons made between individual samples). (N) Heat map depicting selected differentially expressed genes within Hematological System Development, and (O) Cell Growth and Proliferation genes from Ingenuity Pathway Analysis of 34KSL HSCs, Sdc2 HSCs, and Sdc2+ HSCs (n = 10 mice pooled to sort each population; n = 3 replicates per population). Error bars = standard error of the mean; statistics denote 2-way analysis of variance followed by unpaired Student t test. *P < .05, **P < .01, ***P < .001, ****P < .0001. FDR, false discovery rate; ns, not significant; SSC-A, side scatter area.

Close Modal

or Create an Account

Close Modal
Close Modal